QGEN inks an agreement to acquire Genoox for $70 million in cash. The acquisition expands QIAGEN's QDI portfolio.
Qiagen N.V. (NYSE:QGEN ) Q1 2025 Earnings Conference Call May 8, 2025 9:00 AM ET Company Participants John Gilardi - Vice President, Head of Corporate Communications & Investor Relations Thierry Bernard - Chief Executive Officer Roland Sackers - Chief Financial Officer Conference Call Participants Dan Leonard - UBS Doug Schenkel - Wolfe Research Patrick Donnelly - Citi Tycho Peterson - Jefferies Michael Ryskin - Bank of America Jan Koch - Deutsche Bank Jack Meehan - Nephron Research Dan Brennan - TD Cowen Catherine Schulte - Baird Matt Sykes - Goldman Sachs Casey Woodring - JPMorgan Operator Ladies and gentlemen, thank you for standing by.
QGEN's quarterly performance benefits from a resilient portfolio in the first quarter of 2025.
While the top- and bottom-line numbers for Qiagen (QGEN) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Qiagen (QGEN) came out with quarterly earnings of $0.55 per share, beating the Zacks Consensus Estimate of $0.50 per share. This compares to earnings of $0.47 per share a year ago.
Get a deeper insight into the potential performance of Qiagen (QGEN) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Management at Qiagen has done the hard things right, but there is now an opportunity for the company to grow faster and in a more focused way.
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Qiagen (QGEN) and Repligen (RGEN). But which of these two stocks is more attractive to value investors?
Qiagen (QGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
QGEN's robust expansion of its testing menu and potential in molecular diagnostics bode well for investors.